Pathogenic role of the SP/ NK۱R system in GBM cells through inhibiting the thioredoxin system

سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 487

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-24-4_011

تاریخ نمایه سازی: 6 اردیبهشت 1400

چکیده مقاله:

Objective(s): Glioblastoma multiforme (GBM), a highly aggressive Grade IV brain tumor, is a significant public health issue due to its poor prognosis and incurability. Neuropeptide substance P (SP) plays a critical role in GBM tumor growth and development via activation of neurokinin‐۱receptor (NK۱R). Moreover, SP is a pro-oxidant factor contributing to oxidative stress in various cell types. However, the link between SP and oxidative stress in cancer cells is not fully investigated. Here, we aimed to identify the effects of SP and NK۱R antagonist, aprepitant, on the redox status of GBM cells.Materials and Methods: Resazurin assay was employed to determine the effect of aprepitant on viability of U۸۷ glioblastoma cells. ۲’,۷’-dichlorodihydrofluorescein diacetate (H۲DCFDA) assay was employed to measure the levels of intracellular reactive oxygen species (ROS). A quantitative real-time polymerase chain reaction was applied to measure the expression of proteins of the thioredoxin system. Commercial kits (ZellBio GmbH) were also used to measure the enzymatic activity of these proteins.Results: We found that SP increased ROS level in U۸۷ GBM cells, and aprepitant significantly reduced this effect. Furthermore, we found that SP could also affect the thioredoxin system, a central antioxidant enzyme defense system. SP reduced both expression and enzymatic activity of the thioredoxin system’s proteins, Trx and thioredoxin reductase (TrxR) and these effects were significantly reduced by aprepitant. Conclusion: Our results indicated that SP activation of NK۱R represented a link between oxidative stress and GBM and highlighted the need for further validations in future studies.

نویسندگان

Fatemeh Ghahremani

Department of Biology, Faculty of Science, Hakim Sabzevari University, Sabzevar, Iran

Reihaneh Sabbaghzade

Department of Biology, Faculty of Science, Hakim Sabzevari University, Sabzevar, Iran

Safieh Ebrahimi

Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Hosein Javid

Medical Laboratory Sciences Department, Varastegan Institute for Medical Sciences, Mashhad, Iran

Javad Ghahremani

Department of Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Seyed Isaac Hashemy

Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ...
  • 2. Ohka F, Natsume A, Wakabayashi T. Current trends in ...
  • 3. Munoz M, Covenas R. Involvement of substance P and ...
  • 4. Ebrahimi S, Javid H, Alaei A, Hashemy SI. New ...
  • 5. Harrison S, Geppetti P. Substance p. Int J Biochem ...
  • 6. Garcia-Recio S, Gascon P. Biological and pharmacological aspects of ...
  • 7. Suvas S. Role of substance P neuropeptide in inflammation, ...
  • 8. Javid H, Mohammadi F, Zahiri E, Hashemy SI. The ...
  • 9. Javid H, Asadi J, Zahedi Avval F, Afshari AR, ...
  • 10. Mohammadi F, Javid H, Afshari AR, Mashkani B, Hashemy ...
  • 11. Davoodian M, Boroumand N, Mehrabi Bahar M, Jafarian AH, ...
  • 12. Gharaee N, Pourali L, Jafarian AH, Hashemy SI. Evaluation ...
  • 13. Lorestani S, Ghahremanloo A, Jangjoo A, Abedi M, Hashemy ...
  • 14. Palma C, Nardelli F, Manzini S. Correlation between binding ...
  • 15. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi ...
  • 16. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance‐P ...
  • 17. Humphreys S, Pellissier J, Jones A. Cost-effectiveness of an ...
  • 18. Jordan K, Jahn F, Aapro M. Recent developments in ...
  • 19. Robinson P, Taffet G, Engineer N, Khumbatta M, Firozgary ...
  • 20.Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as ...
  • 21. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox ...
  • 22. Springer J, Groneberg DA, Dinh QT, Quarcoo D, Hamelmann ...
  • 23. Gazzieri D, Trevisani M, Springer J, Harrison S, Cottrell ...
  • 24. Liu X, Zhu Y, Zheng W, Qian T, Wang ...
  • 25. Li Q, Wu X, Yang Y, Zhang Y, He ...
  • 26. O’Brien J, Wilson I, Orton T, Pognan F. Investigation ...
  • 27. Sterner-Kock A, Braun RK, van der Vliet A, Schrenzel ...
  • 28. Ma J, Altomare A, de la Monte S, Tong ...
  • 29. Springer J, Pleimes D, Scholz FR, Fischer A. Substance ...
  • 30. Linley JE, Ooi L, Pettinger L, Kirton H, Boyle ...
  • 31. Mohammadi F, Soltani A, Ghahremanloo A, Javid H, Hashemy ...
  • 32.Hashemy SI. The Human Thioredoxin System: Modifications and Clinical Applications. ...
  • 33. Sies H. What is oxidative stress?  Oxidative stress and ...
  • 34. Sanchez-Perez Y, Soto-Reyes E, Garcia-Cuellar CM, Cacho-Diaz B, Santamaria ...
  • 35. Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species ...
  • 36. Afshari AR, Mollazadeh H, Henney NC, Jamialahmad T, Sahebkar ...
  • 37.Jalili-Nik M, Sadeghi MM, Mohtashami E, Mollazadeh H, Afshari AR, ...
  • 38. Ju KD, Lim JW, Kim KH, Kim H. Potential ...
  • 39. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya ...
  • 40. Afshari AR, Roshan MK, Soukhtanloo M, Ghorbani A, Rahmani ...
  • 41. Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols ...
  • 42. Zhao XN, Bai ZZ, Li CH, Sheng CL, Li ...
  • 43. Ge C, Huang H, Huang F, Yang T, Zhang ...
  • 44. Wu H, Cheng X, Huang F, Shao G, Meng ...
  • 45. Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer ...
  • 46. Waris G, Ahsan H. Reactive oxygen species: role in ...
  • 47. Minutoli L, Puzzolo D, Rinaldi M, Irrera N, Marini ...
  • 48. Rinaldi M, Caffo M, Minutoli L, Marini H, Abbritti ...
  • 49. Chien CT, Yu HJ, Lin TB, Lai MK, Hsu ...
  • 50. Chen WC, Shih CC, Lu WA, Li PC, Chen ...
  • 51. Serra MC, Bazzoni F, Della Bianca V, Greskowiak M, ...
  • 52. Block ML, Li G, Qin L, Wu X, Pei ...
  • 53. Rao GM, Rao AV, Raja A, Rao S, Rao ...
  • 54. Lillig CH, Holmgren A. Thioredoxin and related molecules--from biology ...
  • 55. Arner ES, Holmgren A. The thioredoxin system in cancer. ...
  • 56. Hattori I, Takagi Y, Nakamura H, Nozaki K, Bai ...
  • 57. Munemasa Y, Kim SH, Ahn JH, Kwong JM, Caprioli ...
  • 58. Chen Y, Yu M, Jones DP, Greenamyre JT, Cai ...
  • 59. Haas B, Schutte L, Wos-Maganga M, Weickhardt S, Timmer ...
  • نمایش کامل مراجع